All News

The global incidence, deaths, and disability-adjusted life years tied to metabolic dysfunction–associated steatohepatitis (MASH)-related liver cancer have more than doubled in older adults since 1990, with a heavy impact on low- and middle-income countries.

Race, ethnicity, and social factors can influence survival outcomes in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) receiving brexucabtagene autoleucel (brexu-cel).

The findings are part of a new wave of research that uses artificial intelligence (AI) to hasten scientific discovery.

Novel 3D analysis reveals core tumor niches drive resistance through AP-1 signaling and stromal reprogramming.

Cutting-edge therapies can help move the treatment landscape forward, but basic treatment and prevention, such as smoking cessation, are still valuable means of addressing non–small cell lung cancer (NSCLC).

A review of 59 studies finds inconsistent knowledge, attitudes, and practices among health care professionals in detecting diabetic retinopathy.

Male and female fat deposit distribution was associated with an increased cardiovascular age-delta; however, some adiposity phenotypes seen as beneficial in one sex were a risk in the other.

Older survivors of HIV require ethical safeguards and autonomy to feel comfortable participating in end-of-life research for a cure for HIV.

The study found no difference in physician communication scores between patients with advanced cancer and other illnesses, suggesting that discordance may stem from other dynamics.

Evolocumab is now indicated for adults who don’t have a prior cardiovascular disease diagnosis.

A clinical trial assessing a remote weight loss intervention in women with breast cancer saw a reduction in body weight.

Artificial intelligence (AI) can reduce radiologist workload for breast cancer screenings and mammograms, but their review of the results is still crucial, explained Sarah Verboom of Radboud University Medical Center.

New findings demonstrate an association between increased cumulative depression genetic burden and multiple sclerosis (MS) disease activity.

Brensocatib, the first FDA-approved dipeptidyl peptidase 1 (DPP1) inhibitor for non–cystic fibrosis bronchiectasis, may have broader potential for other neutrophil-driven conditions, according to James D. Chalmers, MBChB, PhD.

Clonally expanded CD8+ T cells appear to play a causal role in the initiation and progression of alopecia areata.

Investigators believe the SWIFT-seq system holds potential to replace more invasive bone marrow biopsies.

Brexucabtagene autoleucel shows promising efficacy and safety in treating relapsed B-cell acute lymphoblastic leukemia, including patients with CNS involvement.

Patients reported quality-of-life benefits from treatment for nonsegmental vitiligo, even when clinical improvement started slowly.

Real-world studies reveal limited insights on infection risks for multiple sclerosis patients using disease-modifying treatments, highlighting gaps in clinical trial data.

Patients with chronic lymphocytic leukemia (CLL) had significantly lower monocyte-to-lymphocyte ratio values compared with healthy controls.

A qualitative study found strong support for primary care provider–nephrologist comanagement of chronic kidney disease (CKD), but persistent deficits in CKD understanding remain.

Synthetic generation replicates key clinical patterns from real-world data, enabling valid analyses with fewer patients.

Rising metabolic score for insulin resistance (METS-IR) levels strongly correlate with major cardiovascular events (MACE) and mortality in patients with type 2 diabetes (T2D), according to one study.

Making treatment for non–small cell lung cancer (NSCLC) accessible to a wide range of the population can help to improve outcomes from and knowledge of the condition.

A new study finds that drugmakers’ use of overlapping patents delayed generic entry for 4 top-selling drugs, driving billions in excess spending.

US adults who were displaced and never returned home due to a natural disaster had the highest odds of developing depression or anxiety.

The humanized IgG4 monoclonal antibody was first approved for myasthenia gravis in the US in 2023, with approvals in Japan and the European Union following later that year and 2025, respectively.

James Chalmers, MBChB, PhD, highlights the reassuring safety and tolerability profile of brensocatib in patients with non–cystic fibrosis bronchiectasis.